<DOC>
	<DOCNO>NCT01475110</DOCNO>
	<brief_summary>The GIMEMA CML Working Party promote observational ( retrospective perspective ) study Imatinib-resistant intolerant CML patient treat Nilotinib Italy . Enrollment include patient start Nilotinib January 2005 December 2012 . Patients follow 4 year since treatment start . After time , survival data , disease status treatment record 6-months-interval . This study help definition guideline proper management Nilotinib any-phase CML patient .</brief_summary>
	<brief_title>Observational Study Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib</brief_title>
	<detailed_description>Follow-up required end treatment purpose study patient standard hematologic , cytogenetic molecular criterion . This study contemplate additional expense beyond expect regular follow-up , accord international guideline CML . Sample Size : target accrual define , eligible patient observe January 2005 December 2012 include .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Adult patient Imatinib resistant ( failure + suboptimal ) intolerant chronic myeloid leukaemia phase , start treatment Nilotinib January 2005 December 2012 Italy . Adult pt treat Nilotinib second line therapy Dasatinib . Patients le 18 year old . Use Nilotinib first line treatment . Patients treat Nilotinib 2005 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Imatinib</keyword>
	<keyword>Chronic Myeloid Leukaemia</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Adult patient</keyword>
	<keyword>Imatinib resistant</keyword>
</DOC>